Company intelligence / Profile preview

Aneta Pharmaceuticals

South San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

Aneta Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative small molecule therapies to treat cancer by modulating the tumor microenvironment. The company's lead program, ANET-001, is a potent and selective inhibitor of CD73, an enzyme that plays a critical role in adenosine-mediated immunosuppression within tumors. By blocking CD73, Aneta aims to restore the immune system's ability to recognize and destroy cancer cells. The company is currently evaluating its candidates in early-phase clinical trials for various solid tumors, including pancreatic and lung cancers.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Aneta Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aneta Pharmaceuticals.

Explore the full profile